That’s News

By Hillary Eames
Wednesday, March 11, 2020

Uber in Your EHR?

Nonemergency transportation system Uber Health partnered with Cerner in an agreement that will allow providers to schedule Uber rides for patients directly from Cerner’s EHR — a partnership that should help patients attend their appointments.

The goal of Uber Health is to make health care more accessible to patients who may otherwise struggle to find transportation. Providers with patients who live in ZIP codes without public transportation, for instance, may call Uber Health for their patients to ensure they are able to make their appointments. Patients who have missed appointments in the past may be encouraged to use Uber Health to ensure they visit their healthcare providers in the future.

In regard to data sharing, Uber Health claims to strive to maintain distance between its users and their patient health information and does not share data with third parties or data brokers.

In the future, Uber Health may also expand to include a patient delivery service to provide medical equipment, medications and healthy meals.

Bionic Pancreas Secures Breakthrough Device Designation

The iLet Bionic Pancreas system, a device created by Beta Bionics, received breakthrough device designation from the FDA in December 2019.

The device is capable of delivering both glucagon and insulin analogues to patients with Type 1 diabetes. In a press release, Beta Bionics CEO and President Ed Damiano states that he believes this is a breakthrough therapy in Type 1 diabetes glycemia management.

“We are particularly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people due to its simplicity of use,” Damiano says.

Unlike conventional methods of pump therapy, users are only required to enter their body weight into the iLet system to begin diabetes therapy. From there, the device uses artificial intelligence and machine learning to adapt to users’ individual insulin needs. The device will be able to control blood glucose levels with significantly less input than conventional Type 1 diabetes therapies; patients do not need to deliver correction boluses, count carbohydrates or set delivery rates for insulin.

Additionally, the iLet is the first device of its kind to use a liquid-stable glucagon analogue to improve patient glycemic control. When compared to insulin-only therapy in a 2019 study, the iLet’s bihormonal system proved to be superior in keeping patients’ blood glucose levels within a healthy range.